Prothena Corporation PLC (NASDAQ:PRTA) insider Tara Nickerson sold 4,724 shares of the company’s stock in a transaction dated Wednesday, September 27th. The shares were sold at an average price of $69.05, for a total value of $326,192.20. Following the completion of the sale, the insider now directly owns 6,724 shares of the company’s stock, valued at $464,292.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Tara Nickerson also recently made the following trade(s):

  • On Monday, September 25th, Tara Nickerson sold 17,500 shares of Prothena Corporation PLC stock. The shares were sold at an average price of $63.60, for a total transaction of $1,113,000.00.

Prothena Corporation PLC (NASDAQ:PRTA) opened at 64.77 on Monday. The company’s market cap is $2.48 billion. The firm has a 50-day moving average of $59.56 and a 200-day moving average of $56.28. Prothena Corporation PLC has a 52 week low of $40.58 and a 52 week high of $70.00.

Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The firm had revenue of $26.81 million during the quarter, compared to the consensus estimate of $16.08 million. During the same quarter in the previous year, the company posted ($1.18) earnings per share. The company’s quarterly revenue was up 7951.1% on a year-over-year basis. Equities analysts forecast that Prothena Corporation PLC will post ($4.39) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Prothena Corporation PLC (PRTA) Insider Sells $326,192.20 in Stock” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/prothena-corporation-plc-prta-insider-sells-326192-20-in-stock/1602491.html.

A number of institutional investors have recently added to or reduced their stakes in PRTA. Bank of Montreal Can grew its stake in Prothena Corporation PLC by 6.7% in the 2nd quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 117 shares during the period. Quantbot Technologies LP increased its holdings in Prothena Corporation PLC by 672.7% in the 2nd quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,628 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Prothena Corporation PLC by 187.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 1,549 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Prothena Corporation PLC in the 1st quarter worth about $167,000. Finally, Sei Investments Co. purchased a new stake in Prothena Corporation PLC in the 2nd quarter worth about $176,000.

Several research analysts recently weighed in on the stock. Royal Bank Of Canada reissued a “buy” rating on shares of Prothena Corporation PLC in a research note on Friday. Evercore ISI initiated coverage on shares of Prothena Corporation PLC in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $83.00 target price for the company. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $70.00 target price on shares of Prothena Corporation PLC in a research note on Thursday, July 6th. Zacks Investment Research upgraded shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a report on Friday, August 11th. Finally, BTIG Research cut their target price on shares of Prothena Corporation PLC from $80.00 to $77.00 and set a “buy” rating on the stock in a report on Friday. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $78.58.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Insider Buying and Selling by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.